ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Treatment protocols for lymphoma

Treatment protocols for lymphoma
Literature review current through: Jan 2024.
This topic last updated: May 04, 2022.

INTRODUCTION — The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with lymphoma. This is not an exhaustive list; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with lymphoma. Additional regimens may be added over time, particularly as treatment for lymphoma evolves.

This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with lymphoma. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:

(See "Initial treatment of limited stage diffuse large B cell lymphoma".)

(See "Initial treatment of advanced stage diffuse large B cell lymphoma".)

(See "Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit".)

(See "Initial treatment of stage I follicular lymphoma".)

(See "Initial treatment of stage II to IV follicular lymphoma".)

(See "Treatment of relapsed or refractory follicular lymphoma".)

(See "Initial treatment of peripheral T cell lymphoma".)

These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy and immunotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy and immunotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.

REGIMENS

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone with 21 days between cycles (R-CHOP-21) —  (table 1)

Rituximab plus ifosfamide, carboplatin, and etoposide (R-ICE) —  (table 2)

Cyclophosphamide plus doxorubicin, vincristine, and prednisone with 21 days between cycles (CHOP-21) —  (table 3)

Doxorubicin plus bleomycin, vinblastine, and dacarbazine (ABVD) —  (table 4)

Bendamustine plus rituximab (BR) —  (table 5)

Fludarabine plus rituximab (FR) —  (table 6)

Fludarabine, cyclophosphamide, and rituximab (FCR) —  (table 7)

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (daEPOCH-R) —  (table 8)

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (daEPOCH) —  (table 9)

Pembrolizumab monotherapy —  (table 10)

ACKNOWLEDGMENT — The UpToDate editorial staff acknowledges Scott M Wirth, PharmD, BCOP, who contributed to an earlier version of this topic review.

Topic 85686 Version 24.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟